# Recombinant Mouse FGF21 Protein(Trx Tag)

Catalog Number: PDEM100118



Note: Centrifuge before opening to ensure complete recovery of vial contents.

				ption		
	06		TO T	m	11	$\mathbf{n}$
v					ш	w

Species Mouse

Source Ecoli-derived Mouse FGF21 protein Ala29-Ser210, with an N-terminal Trx

Mol\_Mass 40.0 kDa Accession Q9JJN1

**Bio-activity** Not validated for activity

### **Properties**

**Purity** > 80% as determined by reducing SDS-PAGE.

**Endotoxin** < 10 EU/mg of the protein as determined by the LAL method

Storage Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80

°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of

reconstituted samples are stable at < -20°C for 3 months.


ShippingThis product is provided as lyophilized powder which is shipped with ice packs.FormulationLyophilized from a 0.2 μm filtered solution in PBS with 5% Trehalose and 5%

Mannitol

**Reconstitution** It is recommended that sterile water be added to the vial to prepare a stock solution of

0.5 mg/mL. Concentration is measured by UV-Vis

## Data



SDS-PAGE analysis of Mouse FGF21 proteins, 2µg/lane of Recombinant Mouse FGF21 proteins was resolved with SDS-PAGE under reducing conditions, showing bands at 39 kDa

### Background

Fibroblast growth factor 21 (FGF21) is a member of the fibroblast growth factor (FGF) family. FGF family members possess broad mitogenic and cell survival activities and are involved in a variety of biological processes including embryonic development, cell growth, morphogenesis, tissue repair, tumor growth and invasion. FGF-21 has a hydrophobic amino terminus, which is a typical signal sequence, and appears to be a secreted protein. The metabolic regulator fibroblast growth factor 21 (FGF21) has antidiabetic properties in animal models of diabetes and obesity. FGF21 is a novel adipokine associated with obesity-related metabolic complications in humans. The paradoxical increase of serum FGF21 in obese individuals, which may be explained by a compensatory response or resistance to FGF21, warrants further investigation. FGF-21, which we have identified as a novel metabolic factor, exhibits the therapeutic characteristics necessary for an effective treatment of diabetes.

### For Research Use Only